BioVersys AG (CH:BIOV)
:BIOV
BIOV Stock Chart & Stats
CHF29.60
CHF0.68(1.92%)
At close: 4:00 PM EST
CHF29.60
CHF0.68(1.92%)
Day’s Range― - ―
52-Week RangeCHF21.20 - CHF36.00
Previous CloseN/A
Volume262.00
Average Volume (3M)3.74K
Market Cap
CHF173.12M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.34
Next Earnings
Sep 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding5,848,743
10 Day Avg. Volume2,578
30 Day Avg. Volume3,744
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF55.00Price Target Upside85.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.6
Revenue Forecast (FY)CHF4.65M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy EvidenceA randomized, active-controlled Phase 3 design builds on earlier trial results that showed a clear survival benefit and favorable safety for BV100, supporting its potential in treating highly drug-resistant infections.
Regulatory AdvancementFDA clearance to enroll U.S. patients in the global BV100 Phase 3 program, combined with Qualified Infectious Disease Product designation and constructive engagement with regulators, strengthens the pathway toward potential approval.
Strategic Partnership ExpansionCollaboration and license agreement with Hackensack Meridian adds new ansamycin compounds and brings early-stage infectious disease research expertise, expanding the company's discovery pipeline.
Bears Say
Deal EconomicsUpfront payments and royalty obligations in the collaboration agreement could reduce the company's share of potential future returns from newly licensed assets.
Trial Statistical PowerAdding a small open-label cohort for the most resistant infections may limit statistical power and weaken the trial's ability to demonstrate efficacy in the hardest-to-treat cases.
BioVersys AG News
BIOV FAQ
What was BioVersys AG’s price range in the past 12 months?
BioVersys AG lowest stock price was CHF21.20 and its highest was CHF36.00 in the past 12 months.
What is BioVersys AG’s market cap?
BioVersys AG’s market cap is CHF173.12M.
When is BioVersys AG’s upcoming earnings report date?
BioVersys AG’s upcoming earnings report date is Sep 16, 2026 which is in 164 days.
How were BioVersys AG’s earnings last quarter?
BioVersys AG released its earnings results on Apr 01, 2026. The company reported -CHF1.07 earnings per share for the quarter, the consensus estimate of -CHF1.07 by CHF0.
Is BioVersys AG overvalued?
According to Wall Street analysts BioVersys AG’s price is currently Undervalued.
Does BioVersys AG pay dividends?
BioVersys AG does not currently pay dividends.
What is BioVersys AG’s EPS estimate?
BioVersys AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVersys AG have?
BioVersys AG has 5,848,743 shares outstanding.
What happened to BioVersys AG’s price movement after its last earnings report?
BioVersys AG reported an EPS of -CHF1.07 in its last earnings report, expectations of -CHF1.07. Following the earnings report the stock price went down -0.35%.
Which hedge fund is a major shareholder of BioVersys AG?
Currently, no hedge funds are holding shares in CH:BIOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BIOV Stock 12 Month Forecast
Average Price Target
CHF55.00
▲(85.81% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
RELIEF THERAPEUTICS Holding
―
Options Prices
Currently, No data available
---